ATE388226T1 - Chimerische antisense-oligonukleotide und zelltransfektions-zusammensetzungen davon - Google Patents

Chimerische antisense-oligonukleotide und zelltransfektions-zusammensetzungen davon

Info

Publication number
ATE388226T1
ATE388226T1 AT00959373T AT00959373T ATE388226T1 AT E388226 T1 ATE388226 T1 AT E388226T1 AT 00959373 T AT00959373 T AT 00959373T AT 00959373 T AT00959373 T AT 00959373T AT E388226 T1 ATE388226 T1 AT E388226T1
Authority
AT
Austria
Prior art keywords
block
alkyl
ch2ch2r
formula
twelve
Prior art date
Application number
AT00959373T
Other languages
English (en)
Inventor
Michael Innis
Christoph Reinhard
Ronald Zuckermann
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE388226T1 publication Critical patent/ATE388226T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/317Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/346Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3515Lipophilic moiety, e.g. cholesterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
AT00959373T 1999-08-27 2000-08-25 Chimerische antisense-oligonukleotide und zelltransfektions-zusammensetzungen davon ATE388226T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15124699P 1999-08-27 1999-08-27

Publications (1)

Publication Number Publication Date
ATE388226T1 true ATE388226T1 (de) 2008-03-15

Family

ID=22537917

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00959373T ATE388226T1 (de) 1999-08-27 2000-08-25 Chimerische antisense-oligonukleotide und zelltransfektions-zusammensetzungen davon

Country Status (8)

Country Link
EP (1) EP1144609B1 (de)
JP (1) JP4652648B2 (de)
AT (1) ATE388226T1 (de)
AU (1) AU7070800A (de)
DE (1) DE60038220T2 (de)
ES (1) ES2302699T3 (de)
PT (1) PT1144609E (de)
WO (1) WO2001016306A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057206A2 (en) * 2000-02-03 2001-08-09 Ribozyme Pharmaceuticals, Inc. Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme
US6211164B1 (en) * 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
CA2410516A1 (en) 2000-05-31 2001-12-06 Chiron Corporation Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
EP1950297A2 (de) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und Verfahren zur Behandlung neoplastischer Erkrankungen mithilfe von Chemotherapie und Strahlungssensibilisatoren
ES2305087T3 (es) 2000-06-15 2008-11-01 Novartis Vaccines And Diagnostics, Inc. Polinucleotidos relacionados con el cancer de colon.
ES2300379T3 (es) * 2000-12-23 2008-06-16 Novartis Vaccines And Diagnostics, Inc. Procedimiento de deteccion selectiva de transfeccion de oligonucleotidos.
NZ511705A (en) * 2001-05-14 2004-03-26 Horticulture & Food Res Inst Methods and rapid immunoassay device for detecting progesterone and other steroids
JP3990718B2 (ja) 2003-01-09 2007-10-17 ファイザー・インク キナーゼ阻害剤としてのジアゼピノインドール誘導体
ES2314444T3 (es) 2003-08-29 2009-03-16 Pfizer Inc. Tienopiridina-fenilacetaminasy sus derivados utiles como nuevos agentes antiangiogenicos.
US20050074801A1 (en) 2003-09-09 2005-04-07 Monia Brett P. Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
EP1709195B1 (de) * 2003-12-19 2014-01-22 Novartis Vaccines and Diagnostics, Inc. Zelltransfektionsformulierungen von kleiner interferierender rna, verwandte zusammensetzungen und herstellungsverfahren und verwendung
JP2007530017A (ja) 2004-03-02 2007-11-01 ザ ジョンズ ホプキンス ユニバーシティ ヒトの癌におけるpik3ca遺伝子の変異
CA2686848A1 (en) 2007-05-08 2008-11-20 Schering Corporation Methods of treatment using intravenous formulations comprising temozolomide
JP5576370B2 (ja) 2008-08-06 2014-08-20 ファイザー・インク Chk−1阻害剤としての6置換2−ヘテロシクリルアミノピラジン化合物
US20150010502A1 (en) * 2011-07-13 2015-01-08 Larry J. Smith Compositions and Methods for Suppressing Gene Expression of p53 and Clusterin
EP3856757A4 (de) * 2018-09-28 2022-06-29 Nutcracker Therapeutics, Inc. Tertiäre amino-lipidierte kationische peptide zur nukleinsäureausgabe
AU2020329156A1 (en) * 2019-08-09 2022-03-03 Nutcracker Therapeutics, Inc. Lipidated cationic peptide-PEG compositions for nucleic acid delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935936A (en) * 1996-06-03 1999-08-10 Genzyme Corporation Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
US5849902A (en) * 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
AU738352B2 (en) * 1997-04-30 2001-09-13 Isis Pharmaceuticals, Inc. Oligonucleotides for enhanced bioavailability
US6197332B1 (en) * 1997-08-13 2001-03-06 Chiron Corporation Lipid-conjugated polyamide compounds and related compositions and methods thereof
DE19750702A1 (de) * 1997-11-15 1999-05-27 Hoechst Marion Roussel De Gmbh Antisense Oligonucleotide gegen Tenascin zur Behandlung von Vitiligo
US5958773A (en) * 1998-12-17 1999-09-28 Isis Pharmaceuticals Inc. Antisense modulation of AKT-1 expression

Also Published As

Publication number Publication date
JP2003508459A (ja) 2003-03-04
ES2302699T3 (es) 2008-08-01
PT1144609E (pt) 2008-05-28
WO2001016306A3 (en) 2001-05-10
EP1144609B1 (de) 2008-03-05
DE60038220T2 (de) 2009-03-12
WO2001016306A2 (en) 2001-03-08
AU7070800A (en) 2001-03-26
EP1144609A2 (de) 2001-10-17
JP4652648B2 (ja) 2011-03-16
DE60038220D1 (de) 2008-04-17

Similar Documents

Publication Publication Date Title
ATE388226T1 (de) Chimerische antisense-oligonukleotide und zelltransfektions-zusammensetzungen davon
US9951333B2 (en) Antisense design
Cohen Antisense oligodeoxynucleotides as antiviral agents
EP0832211B1 (de) Spezifische oligonukleotide für hepatitis b virus
Barker Jr et al. Plasmodium falciparum: Effect of Chemical Structure on Efficacy and Specificity of Antisense Oligonucleotides against Malariain Vitro
AU2017232083B2 (en) Amino-LNA, thio-LNA and alpha-L-oxy-LN
HK40119680A (zh) 包含三硫代磷酸酯核苷间键的寡核苷酸
Hayashi et al. Inhibitory effects of modified oligonucleotides complementary to the leader RNA on the multiplication of mouse hepatitis virus

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1144609

Country of ref document: EP